ES2180511T3 - Formulaciones monodispersas de analogos de insulina acilados hexamericos. - Google Patents
Formulaciones monodispersas de analogos de insulina acilados hexamericos.Info
- Publication number
- ES2180511T3 ES2180511T3 ES00904496T ES00904496T ES2180511T3 ES 2180511 T3 ES2180511 T3 ES 2180511T3 ES 00904496 T ES00904496 T ES 00904496T ES 00904496 T ES00904496 T ES 00904496T ES 2180511 T3 ES2180511 T3 ES 2180511T3
- Authority
- ES
- Spain
- Prior art keywords
- formulations
- human insulin
- modified
- acylated
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Una formulación farmacéutica adecuada para su administración a un paciente, que comprende: una solución acuosa con un pH mayor de aproximadamente 7, 9, comprendiendo la solución acuosa: a) un agente de isotonicidad; b) un derivado fenólico; c) iones de cinc; y d) un análogo de insulina humana monoacilado o una sal farmacéuticamente aceptable del análogo de insulina humana monoacilado, comprendiendo el análogo de insulina humana monoacilado o la sal farmacéuticamente aceptable del análogo de insulina humana monoacilado el polipéptido de la SEC ID NO:1 entrecruzado de manera apropiada con la SEC ID NO:2, en el que Xaa en la posición 21 de la SEC ID NO:1 se selecciona entre el grupo compuesto por Asn, Asp, Gly y Glx; Xaa en la posición 3 de la SEC ID NO:2 se selecciona entre el grupo compuesto por Asn, Asp y Glx; Xaa en la posición 28 de la SEC ID NO:2 se selecciona entre el grupo compuesto por Asp, Leu, Val, Ala y Lys acilada; y Xaa en la posición 29 de la SEC ID NO:2 se selecciona entre el grupo compuesto por Pro y Lys acilada; y además, en el que la posición 28 o la posición 29 es Lys acilada, y si la posición 28 es Lys acilada, la posición 29 no es Lys acilada, y si la posición 29 es Lys acilada, la posición 28 no es Lys acilada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11729199P | 1999-01-26 | 1999-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2180511T3 true ES2180511T3 (es) | 2003-02-16 |
Family
ID=22372048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES00904496T Expired - Lifetime ES2180511T3 (es) | 1999-01-26 | 2000-01-26 | Formulaciones monodispersas de analogos de insulina acilados hexamericos. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1146896B1 (es) |
JP (1) | JP2002535287A (es) |
AT (1) | ATE220917T1 (es) |
AU (1) | AU2624400A (es) |
DE (1) | DE60000288T2 (es) |
DK (1) | DK1146896T3 (es) |
ES (1) | ES2180511T3 (es) |
PT (1) | PT1146896E (es) |
WO (1) | WO2000043034A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
ES2360182T3 (es) * | 2002-05-07 | 2011-06-01 | Novo Nordisk A/S | Formulaciones solubles que comprenden insulina monomérica e insulina acilada. |
WO2003094951A1 (en) * | 2002-05-07 | 2003-11-20 | Novo Nordisk A/S | Soluble formulations comprising insulin aspart and insulin detemir |
DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
US7648962B2 (en) | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
US7872095B2 (en) | 2004-07-19 | 2011-01-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
CN101389650B (zh) | 2005-12-28 | 2012-10-10 | 诺沃-诺迪斯克有限公司 | 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法 |
WO2008015099A2 (en) | 2006-07-31 | 2008-02-07 | Novo Nordisk A/S | Pegylated, extended insulins |
CN101541830A (zh) | 2006-09-22 | 2009-09-23 | 诺沃-诺迪斯克有限公司 | 蛋白酶抗性的胰岛素类似物 |
EP2152245B1 (en) | 2007-04-30 | 2015-12-02 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
JP5762001B2 (ja) | 2008-03-14 | 2015-08-12 | ノボ・ノルデイスク・エー/エス | プロテアーゼ安定化インスリンアナログ |
US8691759B2 (en) | 2008-03-18 | 2014-04-08 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
BRPI0919946A2 (pt) | 2008-10-30 | 2016-02-16 | Novo Nordisk As | tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente |
DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
BR112014025132A2 (pt) | 2012-04-11 | 2017-07-11 | Novo Nordisk As | formulações de insulina |
EA034393B1 (ru) | 2012-11-13 | 2020-02-03 | Адосиа | Состав инсулина быстрого действия, содержащий замещенное анионное соединение |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
BR112016007166A2 (pt) | 2013-10-07 | 2017-09-12 | Novo Nordisk As | derivado de um análogo de insulina |
AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
JP6690062B2 (ja) * | 2016-12-16 | 2020-04-28 | ノヴォ ノルディスク アー/エス | インスリン含有医薬組成物 |
EA201992351A1 (ru) | 2017-06-01 | 2020-03-26 | Эли Лилли Энд Компани | Быстродействующие композиции инсулина |
PE20211264A1 (es) | 2017-08-17 | 2021-07-15 | Novo Nordisk As | Analogos de insulina acilados novedosos y usos de estos |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
EP4013778A4 (en) * | 2019-08-16 | 2023-09-13 | Lamark Biotech PVT Limited | FORMULATION OF INSULIN BASED ON CRYSTAL VACCINATION OF HYDROGELS AND METHOD THEREOF |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2182015C2 (ru) * | 1996-06-20 | 2002-05-10 | Ново Нордиск А/С | ПРЕПАРАТ ИНСУЛИНА, СОДЕРЖАЩИЙ NaCl, ПАРЕНТЕРАЛЬНАЯ ГОТОВАЯ ФОРМА, СПОСОБ ПОВЫШЕНИЯ ХИМИЧЕСКОЙ СТАБИЛЬНОСТИ ПРЕПАРАТА ИНСУЛИНА |
EP0966482B1 (en) * | 1997-02-07 | 2005-04-27 | Novo Nordisk A/S | Crystallisation of proteins |
DE69924232D1 (de) * | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
-
2000
- 2000-01-26 AT AT00904496T patent/ATE220917T1/de not_active IP Right Cessation
- 2000-01-26 DK DK00904496T patent/DK1146896T3/da active
- 2000-01-26 ES ES00904496T patent/ES2180511T3/es not_active Expired - Lifetime
- 2000-01-26 DE DE60000288T patent/DE60000288T2/de not_active Expired - Fee Related
- 2000-01-26 WO PCT/US2000/001627 patent/WO2000043034A2/en active IP Right Grant
- 2000-01-26 AU AU26244/00A patent/AU2624400A/en not_active Abandoned
- 2000-01-26 JP JP2000594487A patent/JP2002535287A/ja not_active Withdrawn
- 2000-01-26 PT PT00904496T patent/PT1146896E/pt unknown
- 2000-01-26 EP EP00904496A patent/EP1146896B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE220917T1 (de) | 2002-08-15 |
WO2000043034A2 (en) | 2000-07-27 |
DE60000288T2 (de) | 2003-01-16 |
AU2624400A (en) | 2000-08-07 |
DK1146896T3 (da) | 2002-09-02 |
EP1146896A2 (en) | 2001-10-24 |
EP1146896B1 (en) | 2002-07-24 |
WO2000043034A3 (en) | 2000-12-28 |
PT1146896E (pt) | 2002-10-31 |
DE60000288D1 (de) | 2002-08-29 |
JP2002535287A (ja) | 2002-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2180511T3 (es) | Formulaciones monodispersas de analogos de insulina acilados hexamericos. | |
EP1808438A3 (en) | Purification and stabilization of peptide and proteins in pharmaceutical agents | |
WO2002043750A3 (en) | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations | |
HUP0100243A2 (hu) | Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására | |
EP1234586A3 (en) | Hepatoselective pharmaceutical actives | |
DE58901401D1 (de) | Pharmazeutische zubereitung zur behandlung des diabetes mellitus. | |
IL72033A0 (en) | Oral pharmaceutical compositions containing antidiabetic agents | |
EP2308963A3 (en) | System for processing lipoaspirate cells | |
MY121291A (en) | Fracture healing using pthrp analogs | |
AU563642B2 (en) | Oral antidiabetic composition | |
HK1037142A1 (en) | Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases | |
WO1996024370B1 (en) | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin | |
KR950700326A (ko) | 파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same) | |
HU229598B1 (en) | Preparations for the application of anti-inflammatory agents | |
CA2522146A1 (en) | Uptake of macromolecules | |
IL148797A (en) | Metal-binding compounds and uses thereof |